Cervical cancer is the second most common cancer among women in Ethiopia, with more than 8,000 new cases estimated in 2022. To help prevent future cases, Ethiopia introduced human papillomavirus (HPV) vaccine in 2018. Following the World Health Organization (WHO) recommendation, based on evidence of comparable efficacy and duration of protection of a single-dose HPV vaccine regimen as multiple doses, the country transitioned to a single‑dose regimen in 2024 and carried out a multi‑age cohort (MAC) campaign targeting girls aged 9 to 14 years. This brief summarizes findings from a study conducted by PATH in collaboration with the Federal Ministry of Health on the cost and operational context of HPV vaccine delivery during the MAC campaign.